Oragenics, Inc. (OGEN)
- Previous Close
1.0900 - Open
1.1100 - Bid 1.0500 x 900
- Ask 1.0700 x 800
- Day's Range
1.0650 - 1.0950 - 52 Week Range
1.0100 - 7.7400 - Volume
7,049 - Avg. Volume
99,272 - Market Cap (intraday)
4.774M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-9.1800 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
www.oragenics.comRecent News: OGEN
Performance Overview: OGEN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OGEN
Valuation Measures
Market Cap
4.88M
Enterprise Value
3.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.10
Enterprise Value/Revenue
105.83
Enterprise Value/EBITDA
-0.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-132.48%
Return on Equity (ttm)
-255.36%
Revenue (ttm)
37.65k
Net Income Avi to Common (ttm)
-20.66M
Diluted EPS (ttm)
-9.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
3.48M
Total Debt/Equity (mrq)
10.18%
Levered Free Cash Flow (ttm)
-9.23M